Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if the investigators can use a specific marker in
the pancreatic tumor itself to determine which patients will benefit from receiving
combination chemotherapy of gemcitabine and cisplatin after undergoing resection of a
pancreatic cancer.
The investigators will also investigate if there is any benefit to receiving both
chemotherapy drugs as opposed to only gemcitabine after undergoing complete resection of the
tumor.